1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Company Limited

3692.HK
Hansoh Pharmaceutical Group Company LimitedHK flagHong Kong Stock Exchange
31.94
HKD
+0.78
- -
193.65BMarket Cap
Hansoh Pharmaceutical Group Company Limited
3692.HK
(Hong Kong Stock Exchange)

Recent

price

31.94

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.95
1.08
1.35
1.59
1.48
1.68
1.59
1.71
2.07
2.52
Revenue per Share
0.26
0.28
0.33
0.47
0.44
0.46
0.44
0.55
0.74
0.93
Basic EPS, GAAP
0.17
0.2
0.29
0.5
0.16
0.35
0.41
0.46
0.56
1.05
Free Cash Flow per Basic Share
0.42
0.07
- -
0.27
0.71
0.06
0.12
0.11
0.31
0.34
Dividend per Share
- -
- -
- -
- -
- -
- -
1.33
1.77
2.19
2.78
Book Value per Share
0.5
0.77
0.41
2.38
3.04
3.38
3.82
4.32
4.79
5.87
Tangible Book Value per Share
5,706
5,706
5,706
5,477
5,876
5,921
5,916
5,925
5,930
5,963
Basic Weighted Avg Shares
5,433
6,186
7,722
8,683
8,690
9,935
9,382
10,104
12,261
15,028
Sales/Revenue/Turnover
32.79
30.57
29.43
32.5
32.57
30.55
29.75
28.1
32.88
36.91
Operating Margin (%)
121
138
159
202
233
278
345
366
401
393
Depreciation Expense
1,476
1,595
1,903
2,557
2,569
2,713
2,584
3,278
4,372
5,555
Net Income, GAAP
18.19
17.45
17.59
14.8
17.09
17.79
12.37
12.97
14.03
15.19
Effective Tax Rate (%)
27.17
25.79
24.64
29.45
29.56
27.31
27.54
32.44
35.66
36.97
Profit Margin (%)
1,652
3,190
2,180
11,208
14,596
20,156
23,212
22,020
24,747
31,160
Working Capital
- -
- -
- -
6
82
3,818
4,362
104
61
48
LT Debt
2,974
4,519
2,468
13,044
17,876
20,029
22,647
25,795
28,680
35,364
Total Equity
- -
39.38
50.9
30.55
15.02
11.83
9.54
8.6
11.69
14.52
Return on Invested Capital (%)
- -
159,547,300
190,304,800
53,896.43
5,025.56
140.6
32.74
24.64
31.34
37.32
Return on Capital (%)
- -
159,547,300
190,304,800
9,833,623.08
4,988,168.93
5,217,119.23
65.49
35.63
37.18
37.58
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
14.7%
23.31%
Free Cash Flow
- -
51.67%
87.23%
Net Income, GAAP
- -
17.63%
27.07%
Sales/Revenue/Turnover
- -
12.08%
22.57%
Total Cash Common Dividend
- -
36.18%
8.28%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
10,104
2024
- -
- -
- -
- -
12,261
2025
- -
- -
- -
- -
15,028

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.55
2024
- -
- -
- -
- -
0.74
2025
- -
- -
- -
- -
0.93

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.11
2024
- -
- -
- -
- -
0.31
2025
- -
- -
- -
- -
0.34
Similar Companies
Crescita Therapeutics Inc. (CTX.TO)
Beijing Science Sun Pharmaceutical Co., Ltd. (300485.SZ)
Valiant Laboratories Limited (VALIANTLAB.BO)
Dr. Reddy's Laboratories Limited (RDY)
Nika Pharmaceuticals Inc. (NIKA)
BZAM Ltd. (BZAMF)
Business
Hansoh Pharmaceutical Group Company Limited (3692.HK) is a leading innovation-driven pharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative drugs targeting oncology, anti-infectives, central nervous system diseases, metabolic diseases, and autoimmunity. The company offers a broad portfolio of products including, in oncology, the innovative drugs Ameile (aumolertinib mesylate tablets) and Hansoh Xinfu (flumatinib mesylate tablets), Pulaile (pemetrexed disodium for injection), Xintai (bortezomib for injection), Xinwei (imatinib mesylate tablets), and Tanneng (fosaprepitant dimeglumine for injection); in anti-infectives, the innovative drugs Hengmu (tenofovir amibufenamide tablets) and Mailingda (morinidazole sodium chloride injection), Zetan (tigecycline for injection), and Hengsen (micafungin sodium for injection); in central nervous system diseases, the innovative drug Xinyue (inebilizumab injections, anti-CD19 mAb), Oulanning (olanzapine oral dose formulations), Ailanning (paliperidone extended-release tablets), and Ameining (agomelatine tablets); and in metabolic diseases, the innovative drug Fulaimei (PEG-loxenatide for injection), Fulaidi (repaglinide tablets), and Fulairui (canagliflozin tablets). Founded in 1995 and headquartered in Shanghai with major operations in Lianyungang and Changzhou in Jiangsu Province, China, the company maintains R&D centers in Shanghai, Lianyungang, Changzhou, and Maryland, USA, and conducts business primarily in China while pursuing global partnerships. Recent developments include the National Medical Products Administration's acceptance of the new drug application for HS-10365 capsules targeting RET fusion-positive non-small cell lung cancer in October 2025, approval of a second indication for Xinyue (inebilizumab injection) for IgG4-related disease in September 2025, and granting Roche an exclusive worldwide license (excluding Greater China) to the investigational CDH17-targeting ADC HS-20110 in October 2025 with potential value up to $1.45 billion; the company also presented positive Phase 2 data for HS-20089 (licensed to GSK) in platinum-resistant ovarian cancer and HS-20093 (licensed to GSK) in sarcomas at ESMO 2025, and reported first-half 2025 revenue of RMB 7,434 million, up 14.3% year-over-year, driven by innovative drugs comprising 82.7% of total revenue.